- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| BIOMED LUBLIN Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVONESIS | 56,12 | -0,64 % | Novonesis (Novozymes A/S): Q3 update: Novonesis delivers strong Q3 results and now expects full-year organic sales growth at the upper end of 7-8% | Following increasing demand in the first nine months of the 2024 financial year, Novonesis delivers 9% organic sales growth with a strong 11% organic sales growth in the third quarter. The strong performance... ► Artikel lesen | |
| GENMAB | 199,40 | -2,97 % | Genmab A/S: Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) | Results from Arm 1 of the EPCORE NHL-2 trial show treatment with epcoritamab combination led to an overall response rate (ORR) of 100 percent and a complete response (CR) rate of 87 percent in... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,590 | +3,34 % | Here's Why Arbutus (ABUS) Surged in Q3 | ||
| MOLECULIN BIOTECH | 2,450 | 0,00 % | What's Going On With Moleculin Biotech Shares Wednesday? | ||
| VERICEL | 55,50 | 0,00 % | Vericel-Direktor Paul Wotton verkauft Aktien im Wert von 152.672 US-Dollar | ||
| SENSEI BIOTHERAPEUTICS | 0,403 | -4,50 % | Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights | - SNS-101 Phase 1/2 dose expansion clinical data expected in the first half of 2025 - - Organizational restructuring to focus resources on advancing the clinical development of SNS-101 - ... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 0,443 | +8,79 % | BioXcel Therapeutics Aktie: Ein Wendepunkt ins Negative? | Die BioXcel Therapeutics Aktie verzeichnet zum Ende des Monats November 2024 eine bemerkenswerte Schwächephase. Der aktuelle Kurs von 0,39 EUR spiegelt einen signifikanten monatlichen Rückgang von 31... ► Artikel lesen | |
| MUSTGROW BIOLOGICS | 0,964 | -1,83 % | MustGrow Biologics Corp.: MustGrow Biologics Announces Proposed Private Placement of Units for Approximately $2 Million | Saskatoon, Saskatchewan--(Newsfile Corp. - December 11, 2024) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow") is pleased to announce a proposed non-brokered... ► Artikel lesen | |
| REGENXBIO | 8,800 | -1,12 % | Where Regenxbio Stands With Analysts | ||
| AKEBIA | 1,833 | +0,44 % | Akebia Therapeutics, Inc.: Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights | Vafseo® (vadadustat) on track for U.S. market availability expected in January 2025
Over 300,000 patients, representing approximately 60% of dialysis patient... ► Artikel lesen | |
| FENNEC PHARMACEUTICALS | 5,900 | +0,85 % | Fennec Pharmaceuticals Inc.: Fennec Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update | ~ Achieved Third Quarter 2024 Net Product Sales of $7.0 Million ~ ~ Increasing Momentum and Successful Reimbursement in the Adolescent and Young Adult (AYA) Segment Following Strategic Investments... ► Artikel lesen | |
| REVANCE THERAPEUTICS | 2,900 | 0,00 % | Crown Laboratories, Inc.: Crown Laboratories and Revance Enter into Amended and Restated Merger Agreement | JOHNSON CITY, Tenn. and NASHVILLE, Tenn., Dec. 9, 2024 /PRNewswire/ -- Crown Laboratories, Inc. ("Crown"), a privately held, global innovative leader in the skincare industry, and Revance... ► Artikel lesen | |
| ZEVRA THERAPEUTICS | 8,250 | -2,37 % | Zevra Therapeutics Announces Organizational Changes | CELEBRATION, Fla., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on addressing unmet needs for the treatment... ► Artikel lesen | |
| CORVUS PHARMACEUTICALS | 7,720 | -0,26 % | Corvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis | Adds to growing body of evidence supporting the potential of ITK inhibition as a novel therapeutic for the treatment of a wide range of immune diseases Data will be presented in a poster at ACR Convergence... ► Artikel lesen | |
| CARTESIAN THERAPEUTICS | 21,600 | +3,85 % | Cartesian Therapeutics, Inc.: Cartesian Therapeutics Announces Positive Updated Results from Phase 2b Trial of Descartes-08 in Participants with Myasthenia Gravis and Outlines Design of Planned Phase 3 Trial | Phase 3 AURORA trial on track to commence in 1H2025; Primary endpoint to assess proportion of Descartes-08-treated participants with myasthenia gravis demonstrating an MG-ADL improvement of =3 points... ► Artikel lesen |
Das Unternehmen BIOMED-LUBLIN WYTWORNIA SUROWIC I SZCZEPIONEK SA kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,016 (-1,92 %) liegt der Kurs bei 0,818 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOMED-LUBLIN WYTWORNIA SUROWIC I SZCZEPIONEK SA finden Sie auf Wallstreet Online.
